ADC Technologies | Antibody Drug Conjugate Technology | Abzena

Conjugation Technologies

There are many varieties of antibody drug conjugates technologies available and each has its benefits, though no single one is optimal for every payload and antibody. Abzena offers access to a variety of conjugation technologies for evaluation.

antibody1Disulfide Rebridging – ThioBridge™

ThioBridge™ is Abzena’s proprietary disulfide rebridging linker that delivers more homogeneous ADCs with improved stability. The disulfide bonds are first reduced , but, unlike conjugation using maleimide chemistry, the bond is re-bridged as part of the conjugation process thereby stabilising the tertiary structure of the antibody. Read more >>>

antibody3Cysteine Conjugation

Abzena can engineer unpaired cysteine residues on each heavy chain or exploit interchain disulfide bonds using a engineered cysteines or maleimide or site-specific approach. These approaches allow a DAR of upto 8. Abzena has considerable experience in producing ADCs by these approaches. Read more >>>

antibody4Lysine Conjugation

Lysine conjugation can involve a one or two step processes. A one-step reaction process can be carried out with a pre-formed linker-drug (usually containing a N-hydroxysuccinimide or other activated ester to react with the antibody) to form the ADC. Read more >>>

Other Approaches

Abzena can also perform conjugation using a mixed approach (e.g. Traunt’s reagent), non-natural amino acid incorporation, Enzymatic approaches (e.g. transglutaminase) or Histidine based approach.

Interested in our services? Get In Touch